Use of a DPP-4 inhibitor extends the half-life of native GLP-1, which is as short as 1–2 min under normal physiological conditions5 and therefore permits GLP-1 to restore insulin secretion in T2DM patients, thereby ameliorating their hyperglycaemia. This evidence concerns the gene GLP1R and Hyperglycemia.